Articles tagged with Drug Studies
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A study analyzing NINDS-supported clinical trials found a 4600% return on investment and estimated benefits of over $50 billion. The studies improved health outcomes and saved lives, with some trials showing benefits of over $6 billion.
Chronic pain in elderly population projected to increase by 75% between 2010 and 2030, with limited effective treatment options. Dr. Debra Weiner emphasizes the need for more research to better treat chronic pain in older adults.
A national study reveals that nearly 60% of older diabetics are not taking ACE inhibitors or ARBs, despite clear signs of problems. The study's findings highlight the need for improved awareness and incentives to encourage responsible prescribing and increased use of these life-saving medications.
A UK trial of TeGenero's TGN1412 biological agent resulted in six healthy volunteers developing serious adverse events, highlighting the need for urgent changes to phase I trial authorisation processes. Regulatory bodies must now consider the unique risks associated with activating antibodies compared to conventional drugs.
A new clinical trial launched by Mount Sinai aims to determine whether a combination therapy is more effective than individual treatments in slowing or halting progression of Relapsing-Remitting Multiple Sclerosis. The study will recruit 1000 patients and assess the impact of treatment over 36 months.
Researchers found that older men who drank moderately or heavily and had comorbidities worsened by alcohol use had a 20% higher mortality rate than other drinkers. The study also revealed that lower drinking thresholds should be recommended for older adults with specific conditions.
Treatment with ACE inhibitors significantly reduces risk of death from any cause, cardiovascular death, myocardial infarction and stroke. ACE inhibitors also appear to reduce risk of additional outcomes such as diabetes, congestive heart failure hospitalization and cardiac arrest.
A Hopkins-led clinical study found that men's brains show a significantly higher dopamine release in response to amphetamines compared to women. This discovery may lead to more effective treatments for amphetamine abuse and brain diseases.
The study showed that SB-509 was safe and well-tolerated, with no dose-limiting toxicities observed. Improvements in pain, numbness, and neurological symptoms were seen in approximately 50% of patients, with significant anecdotal improvements reported in neurologic exam scores and electrophysiologic testing.
A study published in Science has found that losartan can prevent the development of aortic aneurysms and potentially reverse damage in mice with Marfan syndrome. This breakthrough discovery increases the likelihood of losartan serving as an effective treatment for humans, offering new hope for those affected by the genetic condition.
Researchers developed a new PET scan technique to detect Alzheimer's disease plaques and tangles, while the ApoE gene was found to significantly increase stroke risk in Asian populations. Foramen ovale closure surgery also showed promise in reducing migraine headaches in patients with an open heart opening.
Studies confirm celecoxib reduces the formation of large intestinal adenomas and incidence of pre-malignant tumors in high-risk patients. Celecoxib also showed reduced risk of advanced neoplasms, severe dysplasia, or invasive cancer.
The study identified a specific genetic profile linked to longevity and favorable lipoprotein profiles in centenarians. The Apolipoprotein C3 (APOC3) SNP was associated with healthier triglyceride and cholesterol levels, lower hypertension rates, and improved cardiovascular health.
A large trial found that vitamin C and E supplements did not reduce the incidence of pre-eclampsia in pregnant women at high risk. However, they were associated with a higher risk of low birthweight babies and increased need for treatment.
The guidelines aim to help physicians decide when to stop taking medications in older adults. They consider factors such as life expectancy, the time until benefits are realized, goals of care, and treatment targets.
Tamoxifen, originally designed as an anti-oestrogen, has proven effective in cancer treatment and is now licensed for preventing breast cancer in high-risk women. Raloxifene, developed to treat osteoporosis, also demonstrates potential in reducing invasive breast cancer risk by 76% in postmenopausal women.
A study presented at the American Academy of Orthopaedic Surgeons annual meeting found that sodium hyaluronate reduced chronic pain in patients with osteoarthritis of the shoulder by nearly 50%. The results were comparable to a previous study that led to the approval of the drug for knee pain, and are being reviewed by the FDA.
In a phase 1 trial, six volunteers received TGN1412 and suffered severe inflammatory reactions, leading to two remaining critically ill. The Lancet urges maximum transparency in clinical trials to reaffirm trust in regulation.
The BRITE-MD trial aims to determine the accuracy of technology in predicting patient response to antidepressants, which could lead to faster recovery times. Preliminary analysis suggests high accuracy rates, but the study is currently recruiting participants.
Pooled data from clinical trials showed significantly fewer patients taking Nexium developed an ulcer compared to those on placebo. The study demonstrated reduced stomach ulcer risk in patients at high risk for complications associated with NSAID use.
Researchers found that donepezil significantly improved cognitive function and daily activities in patients with severe Alzheimer's disease. The study, published in The Lancet, showed a 20% reduction in dementia symptoms and an increase in quality of life for patients on the treatment.
The STAR*D study found that switching to a new medication and augmenting the initial SSRI were effective treatment options for depression. The study showed that all three medications switched to, despite having different mechanisms of action, appeared useful options for treating depression following failure on the first SSRI.
Researchers at Cedars-Sinai Medical Center have identified the potential benefits of Raloxifene in treating advanced prostate cancer. The study showed that Raloxifene can slow or stop the growth of prostate cancer, offering new hope for patients with androgen-independent disease.
A study published in JAMA found that effective treatment of a mother's depression with medication is associated with reduced rates of diagnoses in her children. After three months, children whose mother's depression remitted had a 33% lower rate of psychiatric diagnoses compared to those whose depression remained unresolved.
The European Society of Cardiology recommends that patients taking Clopidogrel should continue their treatment as advised by their physicians. Stopping the anti-clotting drug without consulting a doctor may pose serious risks, according to the ESC.
Researchers have found that combining Lipitor with Glatiramer acetate can prevent or diminish paralysis in mice with experimental autoimmune encephalomyelitis, a model disease closely resembling MS. The study demonstrates the potential of this combination therapy for treating central nervous system autoimmunity.
Discontinuing Plavix in patients with recently-placed stents can lead to clot formation and serious complications. Patients should discuss benefits and risks of anti-clotting medication with their healthcare provider and avoid stopping the medication on their own.
A four-year study of over 800 patients with pre-hypertension found that treatment with candesartan cilexetil significantly reduced the risk of developing hypertension. The study suggests that early intervention may be an effective way to prevent the disease's progression.
A recent study found that fondaparinux significantly reduces the risk of death and reinfarction in patients with STEMI, with benefits observed at 30 days, 9 days, and study end. The treatment also showed a tendency to fewer severe bleeding events.
The ISAR-REACT 2 trial evaluated the value of abciximab in patients with ACS undergoing PCI after pretreatment with 600 mg of clopidogrel. Researchers found that intensive clopidogrel pretreatment plus abciximab may benefit higher-risk patients.
Researchers found that enoxaparin reduced the combined risk of death and MI within 30 days by 17 percent. Enoxaparin also reduced the 30-day risk of nonfatal repeat MI by 33 percent.
A new study demonstrates significant improvements in exercise capacity and left ventricular ejection fraction for patients with advanced coronary artery disease after receiving bone marrow cell therapy. The treatment also shows promise in reducing chest pain and improving daily activities.
Researchers are testing LY450139, a gamma secretase inhibitor, to prevent amyloid plaque build-up and stop Alzheimer's disease progression. The study aims to determine the safety, efficacy, and optimal dosage of the drug in 45 participants.
The OASIS-6 trial evaluated fondaparinux's safety and effectiveness in patients with ST elevation myocardial infarction (STEMI). Fondaparinux prevents amplification of the coagulation system, potentially reducing death risk from heart attacks.
The Trial of Preventing Hypertension study found that early treatment with candesartan reduced the risk of developing hypertension in patients with high normal blood pressure. The study showed a significant benefit from preventive therapy, but lifestyle modification had little effect on public health.
A randomized Phase III clinical trial found decitabine improved treatment outcomes for myelodysplastic syndrome patients, achieving a 17% complete response rate. The median time to progression was also significantly longer in treated patients compared to those receiving supportive care.
Recent studies evaluate the effectiveness of drug-eluting and absorbable stents in treating acute coronary syndromes, including the ACUITY Timing Trial and TAXUS-V ISR trial. The trials suggest that these stents may offer better alternatives to traditional therapies, such as glycoprotein IIb/IIIa inhibitors and vascular brachytherapy.
Researchers found decitabine improves disease-free periods, quality of life in MDS patients. New drug offers little survival benefit but improves quality of life and has some quality of life benefits compared to supportive care.
A study showed that very high-intensity statin therapy can induce regression of coronary atherosclerosis, measured by percent atheroma volume. Rosuvastatin treatment led to significant decreases in low-density lipoprotein cholesterol and increases in high-density lipoprotein cholesterol.
A University of Minnesota study found that telephone support for smokers was more effective in helping them quit than standard medical care. The study, published in Archives of Internal Medicine, showed that 40% of participants who received telephone support had not smoked in the previous seven days after three months.
Recent studies have improved safety and effectiveness in treating patients with acute coronary syndromes, enhancing the management of cardiovascular disease. These advancements include innovative therapies such as bivalirudin and pexelizumab, which aim to reduce major bleeding risks while maintaining efficacy.
The CYPHER stent demonstrated significant lower rates of target vessel failure, repeat revascularization, and major adverse cardiac events compared to bare metal stents. Patients at high-risk for re-blockage also showed improved outcomes without 'late catch-up' in restenosis.
A study of 3,297 elderly residents found that medications prescribed for high blood pressure were associated with a significantly lower risk of developing Alzheimer's disease. Potassium-sparing diuretics showed the strongest link to reduced AD incidence, with increased potassium levels potentially playing a role.
A multicenter randomized trial found that paclitaxel-eluting stents significantly reduce ischemic target vessel revascularization by 40 percent and angiographic restenosis at 9 months compared to VBT. Drug-eluting stents are now considered the treatment of choice for most patients with ISR of previously implanted bare-metal stents.
The TAXUS Express trial showed that paclitaxel-eluting stents reduced restenosis by 40% and cardiac events by 11.5%, compared to vascular brachytherapy. The benefits were achieved without compromising safety, making drug-eluting stents the new standard of care for most patients with restenosis.
A new combination therapy of melphalan, prednisone, and thalidomide has shown significant clinical benefits in elderly multiple myeloma patients. The study found higher response rates and longer event-free survival compared to the standard treatment alone, while also increasing risks of thrombosis, neurological effects, and infection.
Researchers found that cells adapt to low oxygen conditions by inhibiting mitochondrial function and increasing the conversion of glucose to lactate. This active process, mediated by hypoxia-inducible factor-1 (HIF-1), helps protect tumor cells from death and may be targeted by cancer therapies.
A meta-analysis of 24 clinical trials involving over 4,500 pediatric patients found a higher risk of suicidal ideation and behavior when taking antidepressants. The FDA has required warnings and close monitoring for children taking these medications.
Two Stanford University neurologists warn that clinical trials can be disastrous when a drug with unknown side effects is tested on healthy patients. They advocate for stricter entry criteria to prevent similar mistakes in the future.
A study conducted by the NIH and NINDS evaluated patients treated with natalizumab for relapsing-remitting MS and found no new cases of PML. However, the researchers caution that the long-term risk associated with natalizumab treatment is unknown.
A new study found no new cases of progressive multifocal leukoencephalopathy (PML) and confirmed three previously identified cases associated with natalizumab use. The risk of contracting PML may be as low as one in 5,000 or as high as one in 300.
The conference focused on idiosyncratic DILI, a rare form of liver damage caused by genetic and non-genetic factors. Researchers aim to develop diagnostic tools to identify patients at risk, with studies examining DNA, lymphocytes, and serum samples from patients who have experienced and recovered from idiosyncratic DILI.
Researchers seek to confirm that deep brain stimulation can help patients with severe obsessive-compulsive disorder (OCD) and understand the disrupted brain network. A clinical study will examine the effects of DBS at different sites and assess treatment effectiveness.
A new study shows that seasonal intermittent preventive treatment significantly reduces malaria episodes in children under five, with an 86% decrease observed. The treatment, which involves giving antimalarial medication at defined times without prior testing, has the potential to save millions of lives in Africa.
A new study suggests that people who are overweight or obese may have better results with the prescription pill sold as Singulair than with a type of inhaled steroid, while leaner people may have better luck with an inhaled steroid. The findings indicate that obesity may influence individuals' responses to asthma medications.
The GAIT study found that glucosamine and chondroitin sulfate were ineffective in patients with mild knee pain, while those with moderate to severe pain saw significant relief when taking the supplements in combination. The results suggest that a personalized approach to managing osteoarthritis pain may be necessary.
A study of 58 adults with ragweed allergic rhinitis found that both over-the-counter pseudoephedrine and prescription montelukast reduced symptoms, including congestion, runny nose, and sneezing. Pseudoephedrine was more effective at alleviating nasal congestion.
A University of Chicago study found that daily doses of pseudoephedrine hydrochloride were as effective as montelukast sodium in relieving hay fever symptoms without additional side effects. Pseudoephedrine was slightly more effective in reducing congestion and had a lower risk of sleep problems compared to montelukast.
A study by the University of Cincinnati found that a combination of a new medication and ultrasound treatment can reopen blocked brain arteries in nearly 70% of patients. This is an improvement over previous studies, which achieved partial or complete reopening in around 55% of patients.
A new UCLA study published in Science suggests that a farnesyltransferase inhibitor (FTI) may be useful in treating progeria, a genetic disease causing accelerated aging in children. The majority of FTI-treated mice showed improvements in body weight, bone integrity, grip strength, and survival compared to untreated control mice.